Tag: daratumumab

Find relevant news articles from other European projects, below:

CARAMBA  EURE-CART  CARAT Network ATECT PROCROP T2EVOLVE

Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:


Immunotherapy Web Featured Images 109

Browse this week's featured selection of scientific publications

A new selection of scientific publications relating to the latest developments in immunotherapy are added to our website weekly. Here are are a few highlights from this week.

Read more
Immunotherapy Web Featured Images 100

Browse this week's featured selection of scientific publications

A new selection of scientific publications relating to the latest developments in immunotherapy are added to our website weekly. Here are this week's must-read highlights.

Read more
Targeted8

Carfilzomib, Dexamethasone, and Daratumumab Myeloma Treatment Alternative

Hang Quach, MBBS(Hons), SpecCertOC, FRACP, FRCPA, MD, talks about the use of carfilzomib, dexamethasone, and daratumumab as a cheaper alternative for treating relapsed or refractory multiple myeloma as seen in the ALLG MM018/ AMN002 study.

Visit website
Immunotherapy Web Featured Images 81

Use of daratumumab for transplant-ineligible myeloma

During a Targeted Oncology Case-Based Peer Perspective event, Rafael Fonseca, MD, discussed the case of a 72-year-old patient with multiple myeloma.

Visit website
vjhemonic14

DARAZADEX: a Phase II trial of daratumumab plus azacitidine and dexamethasone in...

Nina Shah, MD, University of California-San Francisco, San Francisco, CA, shares the details of an ongoing Phase II trial (NCT04407442) of daratumumab, an anti-CD38 monoclonal antibody, in combination with azacitidine and dexamethasone in relapsed/refractory (R/R) multiple myeloma patients.

Visit website
Immunotherapy Web Featured Images 79

Addition of daratumumab further improves the outcomes for patients with relapsed...

Positive trial results for the anti-CD38 mAb, isatuximab, plus pomalidomide and dexamethasone has led to European approval of this combination, but the regimen requires intravenous administration.

Visit website
ImmunotherapyWebsite Images Featured 16

Phase III CASSIOPEIA Impacts Treatment Decisions in Patients With Multiple Myelo...

Sonneveld says that not only high-risk patients but all those who are transplant-eligible and newly diagnosed may potentially have a new standard of care in the future.

Visit website